trioar Venture Capital
2 known investors
Trioar is a platform company developing next-generation antibody-based technologies to improve the efficacy and therapeutic index of antibody-based therapeutics, including enhanced ADC (antibody-drug conjugate) options. The company focuses on immuno-oncology and cell-targeting therapies for patients with tumors.
Also known as Trioar Β· TRIOAR Β· νΈλ¦¬μ€μ΄
Investors Β· 2
Company profile
researched Aug 2026Trioar (νΈλ¦¬μ€μ΄) is a South Korean biotechnology company developing antibody-based platform technologies intended to address limitations of existing antibody therapeutics. The company positions its next-generation platform as a means of improving the therapeutic index and thereby the overall utility of antibody-based drugs.
The platform combines three described elements: a tumor microenvironment (TME) targeting effector intended to increase drug delivery while suppressing adverse reactions, a tumor-targeting antibody component intended to increase targeting efficacy against cancer cells, and a novel linker-toxin system intended to induce rapid tumor cell death while improving drug stability and potency. Trioar's stated research areas are antibody-drug conjugates (ADCs), in which biologically active drugs or cytotoxic compounds are linked to target-specific antibodies via a linker, and immuno-oncology, focused on strengthening a patient's immune system to find and attack tumors.
The company operates a technology research institute and maintains a pipeline page, and describes an approach based on open collaboration with external experts and joint research to accelerate drug development. It is led by CEO Woo Seong-ho and is headquartered in Yuseong-gu, Daejeon.
Business model
Trioar develops proprietary antibody platform technologies and pipeline candidates and monetizes them through partnerships and technology transfer/licensing to pharmaceutical and biotech companies, as illustrated by its agreements with Celltrion and Daan Bio and its joint PDC development deal with CBioMex.
Revenue is oriented around technology transfer and licensing agreements and co-development contracts with partner companies rather than marketed products.
Traction
Reported milestones include successive financing rounds from pre-Series A through Series B, selection into Korean startup support programs (Baby Unicorn, D-Unicorn, Scale-up TIPS), a win in the 2023 Seoul-BMS Innovation Square Challenge, and partnership and technology transfer agreements with CBioMex, Daan Bio and Celltrion.
Latest developments
In November 2025 Trioar announced an ADC drug development collaboration with Daan Bio and a technology transfer agreement with Celltrion reported at a scale of KRW 522 billion. It was later announced as a Scale-up TIPS selection supporting development of its next-generation ADC platform. In August 2025 it disclosed an additional KRW 2.5 billion investment that brought cumulative Series B funding to KRW 25 billion.
βΈFull profile β market position, technology, go-to-market, geography, history
Market position
Trioar presents itself as an antibody platform development company in the ADC and immuno-oncology fields, recognized through Korean government and municipal startup programs and a Bristol Myers Squibb-affiliated innovation challenge, and has entered licensing and co-development agreements with Korean pharmaceutical companies.
Trioar describes proprietary base technologies accumulated over years of experience, a platform aimed at improving the therapeutic index of antibody-based therapeutics, and a new linker-toxin system intended to deliver faster tumor cell killing with improved drug stability and efficacy. It also cites research infrastructure staffed with domestic and international researchers, a defined drug development strategy, and multiple partnerships.
Technology
An antibody-based platform combining a TME-targeting effector to enhance drug delivery and suppress side effects, a tumor-targeting antibody to improve cancer cell targeting, and a new linker-toxin system for rapid tumor cell killing with improved stability and potency; applied to antibody-drug conjugates and immuno-oncology, and extended to peptide-drug conjugates through partnership.
Go-to-market
The company pursues partnerships and joint research with pharmaceutical and biotech companies and participates in Korean public innovation programs, including the Ministry of SMEs and Startups' Baby Unicorn program, Daejeon City's D-Unicorn Project, and Scale-up TIPS.
Pharmaceutical and biotechnology companies seeking ADC and antibody-based drug technologies, with therapies ultimately aimed at cancer patients.
Geography
Headquartered at 361-17 Gapcheon-ro, Yuseong-gu, Daejeon, South Korea (Room 403), with a website in Korean and English.
History
Public company milestones reported on Trioar's site begin with a PDC co-development agreement with CBioMex in December 2021, followed by a KRW 5 billion pre-Series A in February 2022. In 2023 the company announced a KRW 12 billion Series A (May 2023), was named one of 51 Baby Unicorn companies by Korea's Ministry of SMEs and Startups (May 2023), and won the 2023 Seoul-BMS Innovation Square Challenge (November 2023). It was covered in Daejeon City's third D-Unicorn Project in May 2024. In 2025 the company announced a KRW 22.5 billion Series B (July 2025) and an additional KRW 2.5 billion in August 2025 bringing cumulative Series B funding to KRW 25 billion, alongside several third-party allocation capital increase notices. In November 2025 it announced an ADC development collaboration with Daan Bio and a technology transfer agreement with Celltrion reported at KRW 522 billion. It was subsequently selected for the Scale-up TIPS program.
Compiled by commissioned research from 2 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 16
launches, deals, and filingsTrioar was selected for the Scale-up TIPS program, supporting development of its next-generation ADC platform.
Trioar announced a technology licensing/transfer agreement with Celltrion reported at a scale of KRW 522 billion.
Daan Bio and Trioar began full-scale joint development of ADC drug candidates.
Company announcement of a new KRW 2.5 billion investment, bringing cumulative Series B funding to KRW 25 billion.
Daejeon City launched the third round of its D-Unicorn Project, reported on Trioar's news page.
The Ministry of SMEs and Startups selected 51 Baby Unicorn companies with support of up to KRW 17.3 billion.
Trioar and CBioMex signed a peptide-drug conjugate (PDC) joint development agreement.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 2
primary sources listed
- trioar Venture Capitaltrioar.co.kr Β· web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does trioar Venture Capital do?
- Korean biotech developing next-generation antibody platform technologies for ADCs and immuno-oncology therapeutics.
- Who are trioar Venture Capital's investors?
- trioar Venture Capital's investors include IMM Investment Japan, Kiwoom Investment.